

# The Indian Journal of Genetics and Molecular Research

**The Indian Journal of Genetics and Molecular Research** (Half yearly) will publish high-quality, original research papers, short reports and reviews in the rapidly expanding field of human genetics. The Journal considers contributions that present the results of original research in genetics, evolution and related scientific disciplines. The molecular basis of human genetic disease developmental genetics neurogenetics chromosome structure and function molecular aspects of cancer genetics gene therapy biochemical genetics major advances in gene mapping understanding of genome organization.

---

---

## Printed at

Saujanya Printing Press  
C-97, Okhla Industrial Area  
Phase-1, New Delhi

## Editor-in-Chief

N. Sudhakar  
Associate Professor  
Dr. MGR University  
Chennai

## National Editorial Advisory Board

Anichavezhi, D., Puducherry  
D. Bodhini, Madras Diabetes Research Foundation, Siruseri  
Harashwaradhana, Anthropological Survey of India, Dehradun  
Neerja Gupta, AIIMS, New Delhi  
Niloo Srivastava, DBT, New Delhi  
P.P. Reddy, Hyderabad  
Parimal Das, Associate Professor, Banaras Hindu University,  
Varanasi  
Prakash Gambhir, Marashtra Univ of Health Sciences, Pune  
Priya Tripathi, Chatrapati Sahuji Maharaj Medical University,  
Lucknow  
Ratna D. Puri, New Delhi  
Safrunnisa Mahmood, Chandigarh  
Salgar Somnath Tukaram, Associate Professor, Rural Medical  
College, Loni  
Seema Lekhwani, Pt. B. D. sharma PGIMS, Rohtak  
Sheetal Sharda, Chandigarh  
Sujatha Jagadeesh, Consultant Geneticist & Dysmorphologist,  
Chennai

## International Editorial Advisory Board

Raoul CM Hennekam, University of Amsterdam, The  
Netherlands

## Managing Editor

A Lal

---

---

© 2012 Red Flower Publication Pvt. Ltd. All rights reserved.  
The views and opinions expressed are of the authors  
and not of the **The Indian Journal of Genetics and  
Molecular Research**. The **The Indian Journal of Genetics  
and Molecular Research** does not guarantee directly or  
indirectly the quality or efficacy of any product or service  
featured in the the advertisement in the journal, which are  
purely commercial.

Corresponding address  
**Red Flower Publication Pvt. Ltd.**  
41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I  
Delhi - 110 091(India)  
Phone: 91-11-22754205, Fax: 91-11-22754205  
E-mail: redflowerppl@vsnl.net, Web:www.rfppl.com

# Special Issue

Consensus Statements and abstracts of

National Seminar on  
**Recent Trends in Medical  
Biotechnology**  
21st July 2012

Organized by

Department of Biotechnology  
**Dr. M.G.R. Educational and Research  
Institute University**  
Maduravoyal, Chennai-600095  
Tamil Nadu, India

# The Indian Journal of Genetics and Molecular Research

Volume 1 Number 1

January - June 2012

## *Contents*

---

---

<b>Medical Biotechnology and the Challenge of Chronic disease</b>	7
B.S. Ramakrishna	
<b>Stem Cell Therapy - Liver Disease and Regenerative Medicine</b>	8
Rosy Vennila	
<b>Angiogenesis: The formation of Blood Vessels</b>	9
Suvro Chatterjee	
<b>Microarrays: Bidding Adieu?</b>	10
V.L. Ram Prasad	
<b>Application of Next Generation Sequencing in Fundamental and Clinical Sciences</b>	11
Karthi Sivaraman	
<b>Molecular Pathogenesis of Immune System Disorders</b>	12
Madhumathi	
<b>Biology of Angiogenesis</b>	13
Suvro Chatterjee	
<b>Application of Next Generation Sequencing in Fundamental and Clinical Sciences</b>	14
Karthi Sivaraman	
<b>Study on CD40L mimetic molecules on Dendritic cells</b>	15
S. Sivagami, M. Yogalakshmi, M. Sivanandham	
<b>Stem Cells: A Promising Candidate for cardiovascular Diseases</b>	16
R. Sumathy, M. Vijayalakshmi, M. Deeca Raman	
<b>Applications of Tissue Microarray (TMA) platform for the Molecular characterization of Cancers</b>	17
Siddhartha Roy, K.N.C. Murthy, Chandra Rao Juvva	

<b>Stem cell transplantation and Cancer Treatment: Our experience from a Super-specialty Oncology Hospital</b>	<b>18</b>
Siddhartha Roy, E. Venkataswamy, Vidya Harini Veldore	
<b>Interaction studies of active ingredients of <i>Withania somnifera</i> (Ashwagandha) with Beta-1 adrenergic receptor: A target for Cardiovascular Disease</b>	<b>19</b>
Nitika Sharma, Vidhyalakshmi H, Rekha Ravindran, Sujata Roy	
<b>PknE, a Serine / Threonine kinase from <i>Mycobacterium tuberculosis</i> modulates apoptosis and arginase signalling in macrophages</b>	<b>20</b>
Dinesh Kumar P, Sujatha Narayanan	
<b>Effects of overexpression of signal recognition particle receptor (FtsY) in Mycobacteria</b>	<b>21</b>
Malini Veerasamy, Sujatha Narayanan	
<b>Development of Recombinant BCG Based Epitope Vaccine Candidate for Tuberculosis</b>	<b>22</b>
Aparna Christy, Karthika K.D, P. Kannan and Sujatha Narayanan	
<b>Study of Chick Chorioallantoic membrane to test anti-angiogenesis Activity</b>	<b>23</b>
D. Shanmugapriya, M. Ramya, D. Nithila, R. Jayasree	
<b>Effects of Oxidative stress in Patients with Rheumatoid Arthritis</b>	<b>24</b>
D. Vijayakumar	
<b>Modulatory effect of PPAR gamma agonist pioglitazone on pre-osteoclast cells of Type 2 diabetic subjects</b>	<b>25</b>
Thanigaivelan K, Karpagam V, Shila S.	
<b>Association of Monocyte Chemoattractant Protein (MCP) 1 gene 2518 A/G Polymorphism with Type 2 Diabetic Nephropathy in South Indian Population</b>	<b>26</b>
Yaongamphi Vashum, Md. S. Yasin, B. Thaslima, S. Shila	
<b>Regulatory Role of PPAR gamma Agonist Pioglitazone in Osteoclastogenesis of Type2 Diabetic Postmenopausal Women</b>	<b>27</b>
Zenith Khashim, Shila Samuel	
<b>Association of Endothelial nitric oxide synthase gene Glu298Asp polymorphism in Type 2 diabetic foot ulcer among south Indian population</b>	<b>28</b>
Tholcopiyani.L, Aswini, Santhosh, Arvind Reddy, Hemanth Kumar P, Shila S.	

<b>Study on finding the role of Peroxisome Proliferator – Activated Receptor -<math>\gamma</math> (PPAR-<math>\gamma</math>) agonist Pioglitazone in A549 Lung Adenocarcinoma Cell line</b>	<b>29</b>
Purushoth E, Daphne Bernice V, Shila S.	
<b>In Silico Structure Based Designing of Potent Peptide Inhibitors for Renin and Angiotensin Converting Enzymes</b>	<b>30</b>
Sampoornam B, Shila S.	
<b>Omega-3 Fatty acids from marine microbes</b>	<b>31</b>
Abirami S, Kalpana Balaji, Rajapriya G.	
<b>Screening of Nattokinase Enzyme Producing Microorganisms</b>	<b>32</b>
Rajani Gopal Gad, V. Sheela, S. Nirmala	
<b>Calculation of Secondary structure factors for the Medicinal Plant <i>Cissus quardrangularis</i></b>	<b>33</b>
K. Ramanadhan, V. Dinesh, K. Saranraj	
<b>Targeted drug delivery using niosome: The magic bullet</b>	<b>34</b>
S. Henna Rohiya, B. Jeevitha, A. Grace Agnes, Rekha Ravindran	
<b>Treatment of spinal cord injury using human bone marrow derived neural stem cell-like cells</b>	<b>35</b>
Hemavathy Nagarajan, K.Swetha, V. Varadha Balaji, Millicent Mabel	
<b>Treatment for alkaptonuria by gene therapy</b>	<b>36</b>
B. Vinodhini, M. Swetha, Hemavathy Nagarajan, Millicent Mabel	
<b>Guidelines for authors</b>	<b>40</b>

**The Indian Journal of Genetics and Molecular Research** (Half yearly) will publish high-quality, original research papers, short reports and reviews in the rapidly expanding field of human genetics. The Journal considers contributions that present the results of original research in genetics, evolution and related scientific disciplines. The molecular basis of human genetic disease developmental genetics neurogenetics chromosome structure and function molecular aspects of cancer genetics gene therapy biochemical genetics major advances in gene mapping understanding of genome organization.

### Subscription Information

#### India

Individual

1 year Rs.1000

Life Subscription (Valid for 10 Years) Rs.5000

**Institutional** (1 year) Rs.4000

#### Rest of the World

Individual (1 year) USD100

Institutional (1 year) USD218

### Payment method

#### By cheque/Demand Draft:

Cheque should be in the name of **Red Flower Publication Pvt. Ltd.** payable at Delhi.

By Bank Transfer/TT:

1. **Complete Bank Account No.** 604320110000467

2. **Beneficiary Name (As per Bank Pass Book):** Red Flower Publication Pvt. Ltd.

3. **Address:** 41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091

4. **Bank & Branch Name:** Bank of India; Mayur Vihar

5. **Bank Address & Phone Number:** 13/14, Sri Balaji Shop, Pocket II, Mayur Vihar Phase- I, New Delhi - 110091 (India); Tel: 22750372, 22753401. **Email:** mayurvihar.newdelhi@bankofindia.co.in

6. **MICR Code:** 110013045

7. **Branch Code:** 6043

8. **IFSC Code:** BKID0006043 (used for RTGS and NEFT transactions)

9. **Beneficiary Contact No. & E-mail ID:** 91-11-22754205, E-mail: redflowerpppl@vsnl.net

Send all Orders to: **Red Flower Publication Pvt. Ltd.**, 41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091, India, Phone: 91-11-22754205, Fax: 91-11-22754205, E-mail: redflowerpppl@vsnl.net, Website: www.rfpppl.com.

## Medical Biotechnology and the Challenge of Chronic disease

**B.S. Ramakrishna**

Christian Medical College, Vellore

The field of Medical Biotechnology has changed our lives in the 21<sup>st</sup> century to a great extent in understanding our genome, proteome, metabolome, microbiome, pharmacogenomics, nutrigenomics, nanomedicine, regenerative medicine and so on and so forth. Though the cutting edge technologies are available for diagnostics and therapy, chronic diseases remain a challenging. In India chronic diseases are projected to account for 53% of all deaths. World Health Organization (WHO) projects that in India over the next 10 years more than 60 million people will die from a chronic disease and deaths from infectious diseases, maternal and perinatal conditions, and nutritional deficiencies combined will decrease by 15%. However, the deaths from chronic diseases will increase by 18%.

One such chronic disease is Crohn's disease which causes chronic inflammation of the intestine. It is caused by an abnormal innate immune reaction to intestinal bacteria in an individual of the appropriate genetic makeup. At Christian Medical College, Vellore, over a period of two

decades number of cases diagnosed with Crohn's disease is comparatively higher than that of TB.

TLRs and NOD receptor are two receptor families determine the balance between tolerance and inflammation. NOD2 mutations are associated with ileal crohn's disease in Western countries. Whereas those common NOD2 mutations (R702W, G908R, F1007S) are lacking in Indian patients. Also, known Single Nucleotide Polymorphism (SNPs) in Heat Shock Protein 70, Tumor Necrosis Factor alpha promoter, IL23 receptors are not found in Indian patients with Crohn's disease. Hence, based on the prior experience in immunopathology of the disease, our group has been working on identifying a unique immune footprint for Crohn's disease in Indians.

Using the model of inflammatory bowel disease in Indians, this talk attempts to show how focused research may provide clues that can be translated to therapy or to public health measures that treat or prevent diseases.

## Stem Cell Therapy - Liver Disease and Regenerative Medicine

**Rosy Vennila**

Stanley Medical College, Chennai

The Liver is a complex organ performing several vital functions in man. In acute disease and following surgical resections, the liver can regenerate, wherein the hepatocytes enter the cell cycle and divide repeatedly till the hepatic mass is restored. In the event of chronic injury, the liver loses this capacity to regenerate resulting in Hepatic Failure. Liver Transplantation is the treatment in this situation.

There is a growing interest in the field of Regenerative Medicine, Tissue engineering

and cell therapy. This has triggered research into search for such options to replace Liver transplantation. Stem cells and progenitor cells belonging to various lineages have been identified in Adult Liver. Possibilities exist in the future for use of hepatocytes, stem cells or liver progenitors to treat decompensated Liver diseases.

The Insights provided by such research, as well as the feasibility and hurdles in clinical translation in Hepatology will be discussed.

---

**Red Flower Publication Pvt. Ltd,**

***CAPTURE YOUR MARKET***

**For advertising in this journal**

**Please contact:**

**International print and online display advertising sales**

E-mail: redflowerppl@vsnl.net / tel: +91 11 22754205

**Recruitment and Classified Advertising**

E-mail: redflowerppl@vsnl.net / tel: +91 11 22754205

## Angiogenesis: The formation of Blood Vessels

**Suvro Chatterjee**

AU-KBC Research Centre, Anna University, Chennai

Angiogenesis is a key cellular event essential during growth and development. It involves in the growth of blood vessels by sprouting and intussusception. The interplay maintains a ratio in forming vessels. Shift in the balance leads to an unchecked vessel leads to vascular diseases. Formation of blood vessels follows two morphologically distinct patterns 1) Sprouting and 2) Intussusceptive angiogenesis. Sprouting angiogenesis is the formation of new blood vessel from pre-existing one. Intussusception, an alternative to sprouting mode of angiogenesis, is new blood vessel formation by splitting off existing ones. It is characterized by the

formation of intraluminal pillars within blood vessels and subsequently fuse, which result in vessel expansion and remodeling. The intussusceptive angiogenesis permits rapid expansion of the capillary plexus by creating a hierarchical tree that leads to modification of the branching geometry of supplying vessels. Our work shows that nitric oxide signaling leads to changes in the rate of sprouting and intussusceptive angiogenesis. We aim to elaborate the specific molecular mechanism of nitric oxide signaling in defining the ratio of sprouting and intussusceptive angiogenesis in health and diseases.

## Microarrays: Bidding Adieu?

**V.L. Ram Prasad**

Spinco Biotech, Chennai

A microarray is an analytical device that comprises an array of molecules (oligonucleotides, cDNAs, clones, PCR products, polypeptides, antibodies, and others) or tissue sections immobilized at discrete ordered or nonordered micrometer-to-millimeter-sized locations on the surface of a porous or nonporous insoluble solid support. These devices have been highly effective for the simultaneous detection of large numbers of SNPs/transcripts in a sample, and microarrays have become important analytical tools in many branches of the biological

sciences. A microarray-based analytical strategy is quicker and more convenient than serial testing for each analyte, and it has been successfully applied to both RNA and DNA-based assays. The current scope of microarray applications that includes resequencing, mutation detection, copy number variation, comparative genome hybridization, drug discovery, expression analysis, is shrinking due to the advancements in the Next generation sequencing. Having said that Microarrays continue to play an important role in validation and Diagnostics.

## Application of Next Generation Sequencing in Fundamental and Clinical Sciences

**Karthi Sivaraman**

Next generation Genomics Facility, C-CAMP, Bangalore

Next Generation Sequencing (NGS) has opened the floodgates on biological research in the recent years. Given its ability to interrogate entirely novel genomes, and the ability to aid novel discoveries in well-studied novel systems, NGS has rightly replaced microarrays as the preferred tool for high throughput biological discovery. There are many instances where high throughput sequencing has aided the both fundamental discovery as well as applied sciences. For instance, high throughput sequencing has allowed scientists to understand host specific evolution of uropathogenic *Escherichia coli*. Similarly, genomics has been used to understand the spread and evolution of the *Vibrio cholerae*.

In the first part of my talk, we will see examples of how NGS facilitates the understanding varied biological questions: from plants, to non-model animals, to disease causing pathogens. In the second part, we see how NGS provides a way to understand regulatory networks in pathogens. Last, but not least, NGS technologies provide a window into the fascinating world of cancers. Cancers are diseases of the genome; a case of what happens when genomes go awry. NGS technologies let us have a glimpse of changes that happen within the cancer genome. In the third part of the talk, we will see examples of how NGS technologies lead to better cancer treatment.

## Molecular Pathogenesis of Immune System Disorders

### Madhumathi

Scientist, Stem cell and Molecular Biology Lab, IIT- Madras

Immune system is a highly organized and complex network of tissues, cells and molecules which safeguard the body. The major purpose of the immune system is to defend the body from any infection, foreign molecules or external injury. But if the very system meant to protect falls sick, how would the body respond? The system gets confused and goes haywire resulting in erratic and adverse symptoms. The immune system may become either over-reactive, under reactive or dysregulated. The molecular mechanisms of few of such diseases like Hyper IgE syndrome (genetic disorder), Lymphatic filariasis (parasitic infection) and Lambert-Eaton myasthenic syndrome (autoimmune disease) will be discussed in the talk. Breaching of self and non-self distinction due to genetic anomaly

will result in hyper IgE syndrome characterized by susceptibility to bacterial infection and skin diseases. Similarly when parasitic multi-cellular worms selfishly down regulate immune response of the host to avoid long-term detection, there is again the component of induced anarchy in immune molecular mechanisms. Finally when immune system is auto reactive to neuro receptors there would be progressive loss of muscle weakness attributed to cross-reactive antibodies in the neuro-muscular junction. In conclusion, the talk would attempt to shed light on the existing molecular mechanisms to understand immune disease process for developing viable medical intervention for long-term disease management.

## Biology of Angiogenesis

**Suvro Chatterjee**

AU-KBC Research Centre, Anna University, Chennai

Angiogenesis is a key cellular event essential during growth and development. It involves in the growth of blood vessels by sprouting and intussusception. The interplay maintains a ratio in forming vessels. Shift in the balance leads to an unchecked vessel leads to vascular diseases. Formation of blood vessels follows two morphologically distinct patterns 1) Sprouting and 2) Intussusceptive angiogenesis. Sprouting angiogenesis is the formation of new blood vessel from pre-existing one. Intussusception, an alternative to sprouting mode of angiogenesis, is new blood vessel formation by splitting off existing ones. It is characterized by the

formation of intraluminal pillars within blood vessels and subsequently fuse, which result in vessel expansion and remodeling. The intussusceptive angiogenesis permits rapid expansion of the capillary plexus by creating a hierarchical tree that leads to modification of the branching geometry of supplying vessels. Our work shows that nitric oxide signaling leads to changes in the rate of sprouting and intussusceptive angiogenesis. We aim to elaborate the specific molecular mechanism of nitric oxide signaling in defining the ratio of sprouting and intussusceptive angiogenesis in health and diseases.

## Application of Next Generation Sequencing in Fundamental and Clinical Sciences

**Karthi Sivaraman**

Next generation Genomics Facility, C-CAMP, Bangalore

Next Generation Sequencing (NGS) has opened the floodgates on biological research in the recent years. Given its ability to interrogate entirely novel genomes, and the ability to aid novel discoveries in well-studied novel systems, NGS has rightly replaced microarrays as the preferred tool for high throughput biological discovery. There are many instances where high throughput sequencing has aided the both fundamental discovery as well as applied sciences. For instance, high throughput sequencing has allowed scientists to understand host specific evolution of uropathogenic *Escherichia coli*. Similarly, genomics has been used to understand the spread and evolution of the *Vibrio cholerae*.

In the first part of my talk, we will see examples of how NGS facilitates the understanding varied biological questions: from plants, to non-model animals, to disease causing pathogens. In the second part, we see how NGS provides a way to understand regulatory networks in pathogens. Last, but not least, NGS technologies provide a window into the fascinating world of cancers. Cancers are diseases of the genome; a case of what happens when genomes go awry. NGS technologies let us have a glimpse of changes that happen within the cancer genome. In the third part of the talk, we will see examples of how NGS technologies lead to better cancer treatment.

## Study on CD40L mimetic molecules on Dendritic cells

**S. Sivagami, M.Yogalakshmi, and M. Sivanandham**

Department of Biotechnology, Sri Venkateswara College of Engineering, Sriperumbudur, Chennai-602105, Tamilnadu, India

Dendritic cells are among the most effective antigen presenting cells which are initially immature and have to mature for the induction of an efficient immune response. An important signal for initiating maturation of DCs is through the CD40-CD40L signaling pathway. Activating dendritic cell through CD40L can enhance the immune response. Herein we are introducing Ammonium benzoyl trimethylchloride (ABTC), N Benzhydrylbenzamide (NBB), 3-(Dimethylamino) propiophenone hydrochloride (3-DPH) are CD40L mimetics that was designed using LigBuilder which is a structure based drug design program. These molecules are shown to bind to its cognate receptor CD40 by computational docking.

We utilized dendritic cells from peripheral blood monocytes (PBMC) using

GM-CSF and IL-4 were treated with varying concentrations of these compounds and observed for antigen processing and presentation. Mimetics can stimulate dendritic cell and thereby lead to maturation. The antigen processing capacities of dendritic cells were observed by treating the cells with FITC- Dextran. Although these mimetic molecules are efficient, among these 3-DPH shows good antigen processing capacity in a concentration of 8  $\mu$ M. The differentiation and maturation induction capacity of these organic compounds provides scope for developing it as an alternative to the recombinant CD40L molecules which are prone to degradation.

## Stem Cells: A Promising Candidate for cardiovascular Diseases

R.Sumathy<sup>1,2</sup>, M. Vijayalakshmi<sup>1</sup>, M. Deeca Raman<sup>1</sup>

<sup>1</sup>Dept.of Biotechnology, Dr.MGR Educational Research Institute, Chennai, <sup>2</sup>Dept. of Biotechnology, D.G Vaishnav College, Chennai

Despite the development of new therapeutic strategies and surgical treatments, heart attacks and congestive heart failure remain among the Nation's most prominent health challenges despite many breakthroughs in cardiovascular medicine. Various experimental studies prove that the infusion of stem cells may improve cardiac regeneration in several ways. Moreover, predominantly bone marrow derived cells were shown to restore blood flow, thereby providing a novel therapeutic option for the prevention and/or treatment of heart failure.

Recent research is providing early evidence that adult and embryonic stem cells may be able to replace damaged heart muscle cells and establish new blood vessels to supply them. Thus the adult stem cell therapy today holds the promise of replacing lost heart muscle and enhancing cardiovascular revascularization, thereby treating the cardiovascular diseases promisingly. This is due to plasticity of adult stem cells.

**Keywords:** Stem cells; Cardiac regeneration, Cardiovascular revascularization; Plasticity.

---

---

### Instructions to Authors

Submission to the journal must comply with the Guide for Author.  
Non-compliant submission will be returned to the author for correction.

To access the online submission system and for the most up-to-date version of the Guide for Authors please visit:

<http://www.rfppl.com>

Technical problems or general questions on publishing with IJGMR are supported by Red Flower Publication Pvt. Ltd's Author Support team (<http://www.rfppl.com>)

Alternatively, please contact the Journal's Editorial Office for further assistance.

Publication -in-Charge

**Indian Journal of Genetics and Molecular Research(IJGMR)**

Red Flower Publication Pvt. Ltd.

41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I

Delhi - 110 091, India

Phone: 91-11-22754205, Fax: 91-11-22754205

E-mail: [redflowerppl@gmail.com](mailto:redflowerppl@gmail.com)

Website: [www.rfppl.com](http://www.rfppl.com)

## **Applications of Tissue Microarray (TMA) platform for the Molecular characterization of Cancers**

**Siddhartha Roy, K.N.C. Murthy, Chandra Rao Juvva**

Triesta Reference Laboratory, HealthCare Global Enterprises, Bangalore 560027

Tissue Microarray (TMA) facilitates rapid high throughput analysis and profiling of molecular targets on multiple tissue samples simultaneously. The multifold approach helps parallel reactions to happen at the same time, reducing run-time and minimizing tissue loss or damage. Construction of TMAs comprises of making cylindrical core specimens from 100s of FFPE tissue samples and arranging them in the form of arrays on a TMA block. Each of these blocks can be subjected to molecular reactions at the DNA, RNA or the protein levels. A single TMA procedure can evaluate 100s of samples at the same time for a single target, contrary to conventional practices where only one sample can be characterized at a time. Most of the

applications of TMA have been in the field of cancer research and diagnostics. Examples include qualitative and quantitative evaluation of molecular alterations in tumor samples, analysis of prognostic and predictive markers, search for newer drug targets in the molecular level and understanding of tumor staging and progression. The presentation would comprise of application of TMAs in cancer research, drug development & validation and cross-tissue gene expression studies. We would like to discuss some limitations of TMA platforms, the way it can be automated and with the help of dedicated softwares, the process can be quite fast and sensitive.

## Stem cell transplantation and Cancer Treatment: Our experience from a Super-specialty Oncology Hospital

Siddhartha Roy, E. Venkataswamy and Vidya Harini Veldore

Triesta Reference Laboratory, HealthCare Global Enterprises, Bangalore - 560027

Stem cell transplantation remains the most favored modality in cases of refractory disease in cancer. Chemotherapy and/or radiation therapy at higher doses have a debilitating effect on the regenerative capacity of bone marrow, so Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation help in restoring the stem cells. There are three prevalent modes of transplantation: Autologous (Patient's own stem cells isolated and replaced back), Allogeneic (Compatible donor's stem cells isolated and introduced in the recipient) and Syngeneic (Transplantation among Twins). The motive behind transplanting healthy Stem Cells back into the patient after high doses of chemo and radiotherapies is to rejuvenate bone marrow to regenerate. The whole process takes real-time, round-the-clock monitoring, and decision making on part of the whole team, through number of days.

The stem cells are isolated, accumulated, frozen and then transfused after thawing. Molecular biology techniques like HLA typing, CD34 enumeration by immunophenotyping etc has to be employed for the completion of a successful transplantation procedure. The emergence of Cancer Stem Cells (CSCs) pose a threat as they have properties similar to the native stem cells, so differentiating hematopoietic stem cells from the leukemic stem cells by biomarker characterization is crucial. One approach involves targeting the cancer stem cells by incorporating the fact that hematopoietic stem cells express *Thy-1* and *c-kit* whereas leukemic stem cells express *IL-3* (interleukin-3) receptor  $\alpha$ -chain. We would be presenting the salient features of the three approaches, their advantages and limitations and would share our experience from a cancer super-specialty centre.

## **Interaction studies of active ingredients of *Withania somnifera* (Ashwagandha) with Beta-1 adrenergic receptor: A target for Cardiovascular Disease**

**Nitika Sharma, Vidhyalakshmi H, Rekha Ravindran, Sujata Roy\***

Department of Biotechnology, Rajalakshmi Engineering College, Thandalam, Chennai. \*e-mail:sujataroy@rajalakshmi.edu.in

Cardiovascular Diseases (CVD) remain one of the leading causes of deaths despite several advancements in the medical interventions. The synthetic drugs that constitute the current pharmacological armamentarium are themselves effective in managing the condition by targeting different receptor proteins but not without setbacks. For cardiovascular diseases, herbal treatments have been used in patients with congestive heart failure, systolic hypertension, angina pectoris, atherosclerosis, cerebral insufficiency, venous insufficiency, and arrhythmia. However, many herbal remedies used today have not undergone careful scientific assessment. With the high prevalence of herbal use in the United States/India today, clinicians must inquire about such health practices for cardiac disease and be informed about the potential for benefit and harm. Continuing research is necessary to elucidate the pharmacological activities of

the many herbal remedies which are now being used to treat cardiovascular diseases. Around 80 different validated protein/receptor targets have been identified for CVD's which are associated with different pathways like Calcium signaling pathway, Arachidonic acid metabolism and Metabolic pathways etc. Beta-1 adrenergic receptor is one of the promising targets for cardiovascular disease. Many available drugs are targeting this receptor molecule, example: Acebutolol; Sotalol; Practolol; Levobetaxolol. But those are having some adverse side-effects. So we need molecule with fewer side effects. It has been experimentally established that *Withania somnifera* is beneficial for the heart, but the exact molecular mechanism is not known. The Docking studies revealed that Withaferin-A binds to the active site of Beta-1 adrenergic receptor with significant affinity and its interaction energy is better than Levobetaxolol

## **PknE, a Serine / Threonine kinase from *Mycobacterium tuberculosis* modulates apoptosis and arginase signalling in macrophages**

**Dinesh Kumar P and Sujatha Narayanan**

Department of Immunology, National Institute for Research in Tuberculosis (ICMR), Chennai

### **Introduction**

Pathogenic microbes evade host innate immunity using virulence factors enabling survival and persistence. The mechanisms of immune subversion are of great interest as it provides insights into the pathogenesis and aids in the development of new therapeutics. *Mycobacterium tuberculosis* (MTB), the causative organism of tuberculosis was found to survive inside the macrophages through the inhibition of apoptosis. The aim of the present study was to identify the apoptotic phenotypes suppressed by PknE of MTB.

### **Material and methods**

The THP-1 cell line was differentiated into macrophages and infected with the strains *M. tuberculosis* H<sub>37</sub>Rv (wild-type), *M. tuberculosis* H<sub>37</sub>RvΔPknE (mutant) and complemented H<sub>37</sub>RvΔPknE. On day 5 post infection microarray analysis was carried out. Subsequently the genes involved in

apoptosis, arginase pathway and immune responses, were validated using oligoGE array and qReal-Time PCR.

### **Results**

The deletion mutant of PknE shows a highly activated macrophage transcriptional program. The mutant showed increased pro-apoptotic molecules like BAX, BID of intrinsic pathway of apoptosis with decreased pro-inflammatory cytokines. The decrease in pro-inflammatory response correlated with increased SOCS expression that negatively regulates cytokine signalling. Interestingly, the expression of arginase I, argininosuccinate lyase and iNOS were decreased.

### **Conclusion**

PknE enhances survival of *M. tuberculosis* inside the macrophages by inhibiting signals that activate apoptosis.

Ä

# Effects of overexpression of signal recognition particle receptor (FtsY) in Mycobacteria

Malini Veerasamy and Sujatha Narayanan

Department of Immunology, Tuberculosis Research Centre (ICMR), Chennai - 31

## Introduction

A successful pathogen depends on various factors like cell wall components, secreted proteins and enzymes to survive and persist within the host. Understanding the molecular mechanism that enables the bacteria to sustain harsh and stringent environmental conditions is important to design more effective drugs and vaccines. Studies in prokaryotes have shown that FtsY, a component of signal recognition pathway is involved in membrane protein biogenesis, protein secretion and sporulation. Our aim is to investigate the role of *ftsY* in the growth and survival of *M.tuberculosis* under various conditions.

## Methods

In order to understand the physiological role of FtsY in mycobacterium we used

chemically inducible recombinant *M.smegmatis* mc<sup>2</sup>155 to conditionally overexpress FtsY and subjected them to various invitro stress conditions.

## RESULTS AND CONCLUSION

Overexpression of FtsY retards growth and sliding motility and altered colony morphology. Localization studies by differential centrifugation showed the presence of the protein in the membrane fraction. Attempts to delete *ftsY* failed in producing any knockouts indicating its essentiality. The observed changes warrant further investigation Experiments are being done to confirm its essentiality and future experiments include macrophage assays using the recombinant *M.tuberculosis* overexpressing FtsY.

## Development of Recombinant BCG Based Epitope Vaccine Candidate for Tuberculosis

Aparna Christy, Karthika K.D, P. Kannan and Sujatha Narayanan

Department of Immunology, Tuberculosis Research Centre, Chennai -31

### Introduction

Tuberculosis (TB) remains a global health challenge. BCG, the only available vaccine for TB provides variable efficacy in protection against adult pulmonary TB. Developing better vaccines using novel approaches is a major goal for the TB research community. Epitope-based vaccines designed to induce T cell responses specific for *M.tb* antigens are being developed as one of the means of improving vaccine potential. The aim of our study was to construct a recombinant BCG (rBCG) based epitope vaccine for TB and prove its immunogenicity in a mouse model.

### Materials and Methods

Epitope grafting was done by Splicing by Overlap Extension (SOE) PCR. Expression of the chimeric antigens in BCG was proved by Western blotting. For the immunogenicity experiments, Balb/c mice were immunized subcutaneously with BCG or individual rBCGs. Cell - mediated immune response to specific mycobacterial antigens was studied by evaluation of in vitro splenocyte proliferation (MTT assay) and cytokine estimation (ELISA). Humoral

immune response was studied by measure of serum antibody titre.

### Results

Immunodominant epitopes were chosen from three well defined *M.tb* antigens (CFP-10, FBP and INV2). rBCGs (BCG::Cfp, BCG::Fbp and BCG::Inv) expressing the above epitopes on the *M.tb* Chaperonin 10 back ground of the epitope delivery system was constructed. Expression of chimeric antigens in BCG was verified. Immunogenicity studies show that, compared to BCG vaccinated group the splenocytes derived from rBCG vaccinated groups showed greater antigen specific proliferation, characterized with higher IFN-gamma response and reduced IL-4 secretion. Also rBCG vaccination was able to induce specific humoral immune response with an enhanced IgG2a/IgG1 ratio.

### Conclusion

Our results indicate that the rBCGs favour a Th1 type response, which is known to be important for mycobacterial immunity and are thus promising TB vaccine candidates.

## Study of Chick Chorioallantoic membrane to test anti-angiogenesis Activity

D. Shanmugapriya, M.Ramya, D. Nithila, R. Jayasree

Rajalakshmi Engineering College, Thandalam

Angiogenesis is the term which describes the sequence of events involved in the formation of new blood vessels by damaged tissues. However, a large amount of angiogenesis factors leads to excessive angiogenesis. This is the key factor responsible for the onset of the deadly disease, Cancer. Various anti-angiogenesis therapies are being developed to inhibit the process of angiogenesis, thus, depriving the cancer cells of essential nutrients and finally leading to their death. One such therapy involves the use of plant extracts with anti-angiogenesis properties as an angiogenesis inhibitor. Research is being carried out to improve the efficiency of this therapy. Plants can be regarded as a chemical cocktail composed of diverse chemical components with various biological

activities. In order to improve the effectiveness of the therapy and to reduce the cytotoxic effects of the plant products, the different components of the plant extract can be isolated and various combinations of these components can be tested for their anti-angiogenesis property. Our work involves the study of the chick chorioallantoic membrane of the egg to analyze the anti-angiogenesis activity of test substances. The anti-angiogenesis property of the formulations composed of the different parts of *Allium cepa* (onion), *Fabaceae* (Flame of the forest), *Mentha* (mint) and *Calotropis* were studied.

**Key words:** Anti-angiogenesis, plant extracts, Formulation, Chick chorioallantoic membrane, Cancer.

## Effects of Oxidative stress in Patients with Rheumatoid Arthritis

**D. Vijayakumar**

Arunai College of Engineering, Tiruvannamalai

The main objective of the study was to assess the oxidative stress in plasma and erythrocytes of rheumatoid arthritis patients by measuring the levels of thiobarbituric acid reactive substances (TBARS), non- enzymatic antioxidants (Vitamin E, C & reduced glutathione) and enzymatic antioxidants [(Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSHPX)]. This study has been conducted on twenty adult female rheumatoid arthritis patients and an equal number of healthy subjects. The

levels of TBARS, non-enzymatic antioxidant and enzymatic antioxidants activities were measured using colorimetric methods. In the present study, elevated lipid peroxidation and multidirectional changes in the antioxidant defence system were noticed in patients with rheumatoid arthritis. The enhanced lipid peroxidation accompanied by disturbance in antioxidant status indicates that rheumatoid arthritis patients are more prone to free radical mediated oxidative damage.

## Modulatory effect of PPAR-gamma agonist pioglitazone on pre-osteoclast cells of Type2 diabetic subjects

Thanigaivelan K, Karpagam V, Shila S\*

Department of Biochemistry, VRR Institute of Biomedical Science, (Affiliated to University of Madras), Kattupakkam, Chennai-600056

**Background:** Type2 diabetes mellitus (T2DM) have an increased fracture risk due to anti-diabetic medication use despite a higher bone mineral density (BMD) and increased risk of falls. Pioglitazone is currently the commercially (Actos) available anti-diabetic medicine, a class of Thiozolidinediones (TZDs). PPAR-gamma agonist pioglitazone may cause an increase in osteoclastogenesis in type2 diabetics resulting in reduced bone formation.

**Aim:** To find the effect of PPAR-gamma agonist pioglitazone on osteoclast cell formation derived from T2DM subjects.

**Materials & Methods:** Study subjects included (Group I) healthy subjects (n =10;

M/F: 5/5), Group II T2DM (n=12; M/F: 7/5) and Group III (group II + pioglitazone treatment). Mononuclear cells isolated from peripheral blood from all the study subjects were cultured in an alpha MEM medium containing 10% FBS, 2mM glutamine, 25ng/ml M-CSF, 40ng/ml RANKL, 10mM dexamethasone in the presence of different concentrations of pioglitazone (2,4,6,8,10  $\mu$ M) for 14 days. Cultured cells were stained for TRAP activity using a biochemical kit (Sigma).

**Results & Conclusion:** Pioglitazone stimulated PBMCs from type2 diabetics exhibited a significant increase in number of TRAP positive multinucleated osteoclast cells as compared to untreated cells.

## Association of Monocyte Chemoattractant Protein (MCP) 1 gene 2518 A/G Polymorphism with Type2 Diabetic Nephropathy in South Indian Population

Yaongamphi Vashum, Md. S. Yasin, B. Thaslima, S. Shila\*

Department of Biochemistry, VRR Institute of Biomedical Science (Affiliated to University of Madras), Kattupakkam, Chennai-600056

A promoter polymorphism (-2518 A/G) of Monocyte Chemoattractant Protein (MCP)-1 gene located on chromosome 17 have been studied in different ethnic population in various disease conditions including type 2 diabetes and its complication. The main aim of the present study was to examine the association of G allele frequency of A/G polymorphism of MCP1 gene in South Indian subjects with or without type2 diabetic nephropathy (DN). This study includes 75 diabetic subjects, 75 diabetic subjects with nephropathy and 85 healthy volunteers as control subjects. Genotyping of A/G polymorphism was performed by PCR-RFLP method. The significant difference

was found in age, body mass index, total cholesterol, high density lipoprotein cholesterol, triglyceride, urea and creatinine level, between the case and control subjects. GG genotypic frequency of A/G polymorphism was significantly higher in T2DM diabetic nephropathy subjects (26.67 % vs. 8.24%;  $P=0.001$ ) than in T2DM s (13.33 % vs. 8.24 %;  $P=0.198$ ) and control subjects. G allele frequency was higher in diabetic nephropathy group (49.33 %) than in control subjects (21.18 %). The result obtained in this study shows an increase in the frequency of G-A substitution in MCP-1 gene at position (-2580) among south Indian type 2 diabetic nephropathy subjects.

## Regulatory Role of PPAR-gamma Agonist Pioglitazone in Osteoclastogenesis of Type2 Diabetic Postmenopausal Women

Zenith Khashim, Shila Samuel\*

Department of Biochemistry, VRR Institute of Biomedical Science(Affiliated to University of Madras), Kattupakkam, Chennai-600056

Pioglitazone, a class of Thiazolidinediones (TZDs) is an effective oral drug used for management of type2 diabetes mellitus. Pioglitazone exerts its action through the activation of peroxisome-proliferator activator receptor- $\alpha$  (PPAR-gamma) and turning on gene transcription. Activation of PPAR $\gamma$  by TZDs play an important role in bone metabolism by promoting hematopoietic stem cells to differentiate into osteoclast, thus increasing bone resorption. Many observational studies have suggested the effect of TZDs on bone loss and high fracture incidence in diabetic postmenopausal women; few studies have shown the role of TZDs in estrogen synthesis. The effect of pioglitazone on osteoclastogenesis which may involve the suppression of estrogen function in type2 diabetic postmenopausal women has not been previously studied. In this connection, we have identified osteoclasts in type2 diabetic postmenopausal women using an

invitro technique from peripheral blood monocytes in the presence of macrophage colony stimulating factor (M-CSF) and soluble RANKL.

The study were divided into three groups, healthy control postmenopausal women (n=13) (mean age  $44.61 \pm 17.10$ ), type 2 diabetic postmenopausal women (n=13) (mean age  $48.87 \pm 16.98$ ) and type 2 diabetic premenopausal women (mean age  $32.12 \pm 7.10$ ) (n=13). PBMCs were treated with different concentrations of pioglitazone (2-10 $\mu$ M) and 17 beta estradiol (0.1-1nM) for 7-15 days. TRAP-positive multinucleated cells containing three or more nuclei were considered as osteoclasts. Pioglitazone treated cells showed a significant increase in osteoclasts as compared with untreated cells from healthy and diabetic pre and postmenopausal women. Reduction in osteoclast cells were observed in estradiol treated cells as compared to untreated cells.

## Association of Endothelial nitric oxide synthase gene Glu298Asp polymorphism in Type2 diabetic foot ulcer among south Indian population

Tholcopiyani.L<sup>1</sup>, Aswini<sup>2</sup>, Santhosh<sup>3</sup>, Arvind Reddy<sup>4</sup>, Hemanth Kumar P<sup>5</sup>, Shila S<sup>6</sup>

<sup>6</sup>Department of Biochemistry, VRR Institute of Biomedical Science (Affiliated to University of Madras), Kattupakkam, Chennai-600 056, India, <sup>4</sup> Vellore Diabetes Clinic, Vellore, Tamilnadu, India, <sup>5</sup>St John's Medical College Hospital, Bangalore, Karnataka, India

**Background:** Diabetic foot complications has become one of the most common causes of nontraumatic lower extremity amputations in the world. Diabetic foot ulcer is a pathological condition where a decreased nitric oxide may present. In recent years, eNOS gene polymorphism (Glu298Asp) has gained enormous attention due to their association with diabetes mellitus regulation.

**Materials & Methods:** The study group consisted of 133 type2 diabetic foot ulcer subjects and 147 healthy volunteers as controls. 500µl of blood sample was used to isolate genomic DNA by Phenol-chloroform method. PCR amplification was carried out with suitable forward 5' TCC CTG AGG GCA TGAGGCT 3' and reverse 5' TGA GGG TCACAC AGG TTC CT 3' primers, followed by *BanII* restriction digestion enzyme and the products

(137bp,320bp,457bp) were analysed using 2% agarose gel electrophoresis.

**Results:** Allele and genotype frequencies in both groups were analysed by student's t-test. 101 of 133 diabetic subjects had GG genotype, 29 had GT genotype and 3 had TT genotype. 133 of 147 controls showed GG genotype, 13 showed GT genotype and 1 showed TT genotype. The genotypic frequencies for Glu298Glu, Glu298Asp, Asp298Asp were 0.904(n=133), 0.088(n=13), and 0.06(n=1) in control group and 0.759(n=101), 0.218(n=29) and 0.022(n=3) in type2 diabetic foot ulcer group. The positivity for Asp allele was significantly increased in type2 diabetic foot ulcer than in controls (P=0.008).

**Conclusion:** The present study finds that there was a significant association of the Glu298Asp variant polymorphism of the eNOS gene with diabetic foot ulcer.

## Study on finding the role of Peroxisome Proliferator - Activated Receptor - $\gamma$ (PPAR- $\gamma$ ) agonist Pioglitazone in A549 Lung Adenocarcinoma Cell line

Purushoth E<sup>1</sup>, Daphne Bernice V<sup>2</sup>, Shila S<sup>2</sup>

<sup>1</sup>SRM Medical College Hospital and Research Centre, SRM University, <sup>2</sup>Udaya School of Engineering, Udaya Nagar, Vellamodi, <sup>3</sup>VRR Institute of Biomedical Science, kattupakkam, Chennai - 56

**Background:** Pioglitazone is a synthetic ligand of nuclear receptor peroxisome proliferator-activated receptor PPAR- $\gamma$  that is approved for the treatment of type2 diabetes mellitus. PPAR- $\gamma$  has been associated with anticancer activities in a variety of cancer cell lines through inhibition of proliferation and promotion of apoptosis. The exact mechanism of PPAR- $\gamma$  to cancer growth inhibition remains unclear.

**Aim:** The present study is aimed to find the anti-proliferative and apoptotic effect of pioglitazone on lung adenocarcinoma cell lines (A549.).

**Materials and Methods:** A549 Lung adeno carcinoma cell line was used for the study. Cells were treated with different concentrations of pioglitazone (5, 25, 50,100  $\mu$ M). The cytotoxic effect was assessed by Tryphan blue assay and apoptosis by DNA fragmentation assay and protein expression of PPAR- $\gamma$  and MMP 9 by western blot technique.

**Results:** On treatment with pioglitazone, the morphology of A549 cells was changed in a time and dose dependant manner. At 100 $\mu$ M concentration, the change in cell morphology was observed immediately. The percentage of viability showed significant ( $p<0.05$ ) reduction of viable cells at 100  $\mu$ M concentration at 24h and 48h and more significant ( $p<0.01$ ) at 72h. At 25 and 50  $\mu$ M concentration the significance ( $p<0.05$ ) was observed from 48hrs. Treated cells showed significant increase in PPAR- $\gamma$  expression with respect to the increasing dose, but MMP 9 expression was decreased with respect to higher dose. The DNA fragmentation results showed multiples of 180 bp, and produced band width of 1440 and 720 bp at the concentration 100  $\mu$ M.

**Conclusion:** It is concluded that pioglitazone causes change in cell morphology, reduction in cell viability, DNA fragmentation and inhibition of MMP 9 expression by activation of PPAR- $\gamma$  expression.

## **In Silico Structure Based Designing of Potent Peptide Inhibitors for Renin and Angiotensin Converting Enzymes**

**Sampoornam B, Shila S.**

Department of Biochemistry, VRR Institute of Biomedical Science (Affiliated to University of Madras), Kattupakkam, Chennai-600 056, India

The enzymes Renin and Angiotensin Converting Enzymes (ACE'S) are associated with hypertension, congestive heart failure and diabetic nephropathy. Renin is a protease and ACE's are carboxy peptidases. There are three kinds of ACE's in humans (evidence from databases). Renin is a prohormone acting on free floating angiotensinogen. All the three ACE's are membrane bound, one of the receptors of insulin participating in signal transduction and involved in the conversion of Angiotensin I to Angiotensin II, a potent vaso constrictor involved in raising blood pressure. These ACE's and renin are crucial key targets for development of drugs. The so-called anti hypertensive drugs used for treating hypertension are having their plasma half life less than that of their target

enzymes. So this study was proposed with the aim to design peptide aptamers for all these enzymes. Computational tools such as Swiss model and Thematics server were used to design the 3D structure of all the enzymes and for identification of target sites. The small peptide aptamers were designed using the molecular builder tool of the Argus lab software and the target sequences were built into small peptide chains and then both the targets and aptamers were converted into PDB format. Docking results on this peptide using Hex software indicated that the peptide has potency to bind to the target sites on the enzymes. The proposed, small peptide has shown all the desirable features of a potent inhibitor and hence it may be a potential lead compound.

## Omega-3 Fatty acids from marine microbes

**Abirami S\*, Kalpana Balaji, Rajapriya G.**

SynkroMax Biotech Pvt Ltd, Chennai 600116

Omega-3 fatty acids regularly make headlines for their potential to prevent cardiovascular diseases, asthma, depression etc. Evidently, n-3 fatty acids reduce blood triglycerides level and regular intake reduces the risk of secondary and primary heart attack. Long chain EPA/DHA omega-3 fatty acids supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3 fatty acids for health benefits and natural medicine in several major diseases, hence global fisheries are generally acknowledged to be threatened indicating a requirement for new and sustainable sources of n-3 oils. New

sources of these oils would reduce pressure on declining fish resources worldwide.

This presentation deals with the molecular effects of n-3 fatty acids on coronary heart disease, cancer, atherosclerosis, type II diabetes and need for alternative mean for the synthesis of beneficial polyunsaturated fatty acids considering of aquatic population. Marine microorganisms have been isolated and are found to be efficient producers of EPA and DHA. Identifying and characterizing molecules in the omega-3 fatty acid pathway will help the pharmaceutical industry to explore drugs that mimic these compounds.

## Screening of Nattokinase Enzyme Producing Microorganisms

Rajani Gopal Gad<sup>\*1,2</sup>, V Sheela<sup>1</sup>, S Nirmala<sup>2</sup>

<sup>1</sup>Synkromax Biotech Pvt Ltd, Chennai, India, <sup>2</sup>SRM University, Ramapuram Campus, Chennai, India

Nattokinase is a potent fibrinolytic enzyme, which belongs to the group of alkaline serine protease. Nattokinase was first derived from *Bacillus subtilise var natto*, isolated from traditional Japanese soybean food, Natto. This enzyme offers a completely natural means of preventing and dissolving blood clots. It closely resembles plasmin and actually enhances the production of plasmin. It is a potent cardiovascular drug and the enzyme activity is enhanced in the plasma for a longer half-life with oral administration. Compared with conventional clot dissolving drugs, Nattokinase has several advantages, such as, safety, convenience, oral administration, confirmed efficacy, prolonged effects, preventive effect, low cost and stability in gastrointestinal tract and these characters make Nattokinase a promising oral medicine for thrombolytic therapy.

Nattokinase is truly a multidimensional nutrient supplement and can play a key role in treating hypertension and hypercoagulation. It has a 4-fold greater thrombus dissolving ability than plasmin and very efficiently initiates endogenous

fibrinolysis by cleavage and inactivation of plasminogen activator inhibitor-1. This ultimately leads to efficient lysis of detrimental coagulation of blood in the body. This enzyme is classified under Nutraceuticals and available as an OTC product. Best Nattokinase, New Nattokinase, Nattokinase X-tra, Nattozymeetc are some of the brand names available in the market..

In this research work, as a first step, massive isolation work was carried out in order to screen for Nattokinase producing microorganisms. Seventy cultures were isolated from various sources and preliminary plate assay method (hydrolysis of casein) was carried out. Out of these seventy cultures, thirty three were shortlisted, which were very much positive in the preliminary plate assay method. *Bacillus sp*, which exhibited high enzyme activity at pH 8.0 and above and at a temperature of 37°C was selected for further studies. The physiochemical properties of these enzymes have been characterized and their effectiveness in thrombolysis *in vitro* has been further studied.

## Calculation of Secondary structure factors for the Medicinal Plant *Cissus quardrangularis*

**K.Ramanadhan, V. Dinesh, K.Saranraj**

Department of Biotechnology, Thanthai Hans Roever College, Permabalur, Chennai

We have concentrated in the medicinal plant *Cissus quardrangularis* to study its emerging medicinal value. We have retrieved a particular protein sequence of *Cissus quardrangularis* from NCBI databank. Then the retrieved sequence was subjected to swiss pdb viewer to predict primary structure. We have also concentrated in the secondary structural factors for this plant.

The secondary structure factors have been calculated by Expasy server. From these results, we have observed that the composition of structural factors were very high. So, we have concluded that these structural parameters may be useful for the process of drug designing. *Cissus quardrangularis* has the anti fungal and anti bacterial activity.

## Targeted drug delivery using niosome: The magic bullet

**S. Henna Rohiya, B. Jeevitha, A. Grace Agnes, Rekha Ravindran**

Department of Biotechnology, Rajalakshmi Engineering College, Chennai - 602105

### Objective

To achieve targeted drug delivery using Niosomes- "The Magic Bullet"

### Abstract

Niosomes are microscopic lamellar structure formed on admixture of non-ionic surfactant of the alkyl or dialkyl poly glycerol ether class and cholesterol with subsequent hydration in aqueous medium. Types: 1) SUV-Small Unilamellar Vesicle, 2) MLV-Multi Lamellar Vesicles, 3) LUV-Large Unilamellar Vesicles. Niosomes are designed to concentrate the drug to the tissue of interest as a result drug is localized on the targeted site. Hence, healthy tissues are not affected by the drug. The properties of the vesicles can be changed by varying the composition of vesicles, size, lamellarity, tapped volume, surface change and concentration.

### Advantage

Niosomes are the best carrier as they act as a depot releasing the drug in the controlled manner, variety of drugs can be loaded due to hydrophilic, lipophilic nature, exhibits flexibility in structural characteristics, osmotically active and stable, surfactants are biodegradable, biocompatible, and non immunogenic.

Therapeutic applications include (1) Targeting of bioactive agents to Reticulo Endothelial Systems, (2) Delivery of peptide drugs, (3) Carrier for haemoglobin.

### Conclusion

Niosomes are the promising targeted drug delivery system since they are cost effective and prepared from uncharged single chain surfactant and cholesterol.

## Treatment of spinal cord injury using human bone marrow derived neural stem cell-like cells

Hemavathy Nagarajan, K.Swetha, V. Varadha Balaji, Millicent Mabel

Rajalakshmi Engineering College, Thandalam, Chennai-602 105

### Background

Stem cells have enormous potential to differentiate or transform into a diverse range of specialized cells that make humans what they are today. In the face of complications that are known to arise during spinal cord injury treatments like laminectomy and open decompression, one has to devise a safer procedure, which brings our focus on stem cell engineering.

### Objective

In Stem cell treatment for spinal cord injury, the isolation and culturing of Neural Stem Cells (NSCs) is an arduous process and the alternative and effective method could be trans-differentiation of human adult Bone Marrow Stromal Cells (hMSC) into the Neural Stem Cell-like cells (hmNSCs). This could increase the feasibility of spinal cord injury treatment over existing methods, while improving its economical viability.

### Method

Mesenchymal Stem Cells are isolated from adipose tissue, umbilical cord blood, periosteum, synovial membrane, muscle, dermis, blood, bone marrow, trabecular bone. The culture expansion of hMSCs is followed by its conversion into neuroprogenitor-like cells and the osteogenic, chondrogenic adipogenic neurogenic differentiation of the cultured cells are performed by adhering to standard protocols. These cells, after proper analysis like clonal analysis, can be used for spinal cord repair and other related disorders.

### Conclusion

Economical feasibility and efficacy of the proposed idea would promote an unbiased chance of undergoing this inexpensive treatment. However, only after conclusive experimental trials the success rate and potential use of this futuristic technology will be deduced.

## Treatment for alkaptonuria by gene therapy

**B. Vinodhini, M. Swetha, Hemavathy Nagarajan, Millicent Mabel**

Rajalakshmi Engineering College, Thandalam, Chennai

### Background

Alkaptonuria (AKU), the prototypic inborn error of metabolism, was the first human disease to be interpreted as a mendelian trait. Alkaptonuria is a disorder caused by deficiency of recessive homogentisate 1,2 dioxygenase, an enzyme required for the catabolism of phenylalanine and tyrosine in liver and kidney.

### Objective

The defect is caused by mutation in HGD gene that maps to human chromosome 3q21-q23. CCC sequence motif is a mutational hot spot in homogentisate-1,2-dioxygenase gene.

### Methodology

A total of 43 single residue substitutions impairing HGO enzyme activity have been identified in AKU patients and model organisms. For mutation analysis, 10 ml EDTA

blood samples were obtained from two different group of subjects, one unaffected and the other affected. Genomic DNA was isolated from leukocyte nuclei and the sequence differences were analyzed by single stranded conformational analysis (SSCA). Since, a substitution of the amino acid valine for methionine at position 368 (Met368Val) is the most common HGD mutation. Mutations in the HGD gene probably inactivate the enzyme by changing its structure. Therefore gene therapy has to be implemented by changing the amino acid sequence.

### Conclusion

If being diagnosed earlier in foetus, the gene therapy method can easily be implemented. In adults, reduction in intake of phenylalanine rich food can help in reducing the

Accumulation of HGA and thus will reduce the symptoms of alkaptonuria.

### Library Recommendation Form

If you would like to recommend this journal to your library, simply complete the form below and return it to us. Please type or print the information clearly. We will forward a sample copy to your library, along with this recommendation card.

**Please send a sample copy to:**

Name of Librarian

Library

Address of Library

**Recommended by:**

Your Name/ Title

Department

Address

**Dear Librarian,**

I would like to recommend that your library subscribe to the **Indian Journal of Genetics and Molecular Research**. I believe the major future uses of the journal for your library would be:

1. As useful information for members of my specialty.
2. As an excellent research aid.
3. As an invaluable student resource.
4. **I have a personal subscription and understand and appreciate the value an institutional subscription would mean to our staff.**
5. Other

Should the journal you're reading right now be a part of your University or institution's library? To have a free sample sent to your librarian, simply fill out and mail this today!

Stock Manager

**Red Flower Publication Pvt. Ltd.**

41/48, DSIDC, Pocket-II, Mayur Vihar, Phase-I

P.O. Box No. 9108, Delhi - 110 091 (India)

Tel: 91-11-65270068, 22754205, Fax: 91-11-22754205

E-mail: redflowerpppl@gmail.com, redflowerpppl@vsnl.net

Website: www.rfppl.com

**BOOKS FOR SALE****CHILD INTELLIGENCE****By Dr. Rajesh Shukla**

ISBN: 81-901846-1-X, Pb, vi+141 Pages

Price: Rs.150/-, US\$50/-

Published by **World Informations Syndicate**

This century will be the century of the brain. Intelligence will define success of individuals; it remains the main ingredient of success. Developed and used properly, intelligence of an individual takes him to greater heights. Ask yourself, is your child intelligent! If yes, is he or she utilizing the capacity as well as he can? I believe majority of people, up to 80% may not be using their brain to best potential. Once a substantial part of life has passed, effective use of this human faculty cannot take one very far. So, parents need to know how does their child grow and how he becomes intelligent in due course of time. As the pressure for intelligence increases, the child is asked to perform in different aspects of life equally well. At times, it may be counter-productive. Facts about various facets of intelligence are given here. Other topics like emotional intelligence, delayed development, retardation, vaccines, advice to parents and attitude have also been discussed in a nutshell. The aim of this book is to help the child reach the best intellectual capacity. I think if the book turns even one individual into a user of his best intelligence potential, it is a success.

**PEDIATRICS COMPANION****By Dr. Rajesh Shukla**

ISBN: 81-901846-0-1, Hb, VIII+392 Pages

Price: Rs.250/-, US\$50

Published by **World Informations Syndicate**

This book has been addressed to young doctors who take care of children, such as postgraduate students, junior doctors working in various capacities in Pediatrics and private practitioners. Standard Pediatric practices as well as diseases have been described in a nutshell. List of causes, differential diagnosis and tips for examination have been given to help examination-going students revise it quickly. Parent guidance techniques, vaccination and food have been included for private practitioners and family physicians that see a large child population in our country. Parents can have some understanding of how the doctors will try to manage a particular condition in a child systematically. A list of commonly used pediatric drugs and dosage is also given. Some views on controversies in Pediatrics have also been included. Few important techniques have been described which include procedures like endotracheal intubations, collecting blood samples and ventilation. I hope this book helps young doctors serve children better.

**Order from**

Red Flower Publication Pvt. Ltd.

41/48, DSIDC, Pocket-II, Mayur Vihar, Phase-I

P.O. Box No. 9108, Delhi - 110 091 (India)

Tel: 91-11-65270068, 22754205, Fax: 91-11-22754205

E-mail: redflowerpppl@gmail.com, redflowerpppl@vsnl.net

**Revised Rates for 2012 (Institutional)**

<b>Title</b>	<b>Freequency</b>	<b>Rate (Rs): India</b>	<b>Rate (\$):ROW</b>
Indian Journal of Anatomy	2	2500	260
Indian Journal of Ancient Medicine and Yoga	4	6000	300
Indian Journal of Dental Education	4	2500	240
Indian Journal of Emergency Pediatrics	4	5000	252
Indian Journal of Forensic Medicine & Pathology	4	10000	480
Indian Journal of Forensic Odontology	4	2500	240
Indian Journal of Genetics and Molecular Research	2	4000	218
Indian Journal of Library and Information Science	3	6000	500
Indian Journal of Pathology: Research and Practice	3	19000	795
Indian Journal of Pediatric Education	4	3000	150
Indian Journal of Surgical Nursing	3	1200	57
Journal of Psychiatric Nursing	3	1200	57
International Journal of Neurology & Neurosurgery	2	6000	230
Journal of Social Welfare and Management	4	6000	230
New Indian Journal of Surgery	4	6000	300
Physiotherapy and Occupational Therapy Journal	4	6000	300

1. Advance payment required by Demand Draft payable to Red Flower Publicaion Pvt. Ltd. payable at Delhi.

2. Cancellation not allowed except for duplicate payment.

3. Agents allowed 10% discount.

4. Claim must be made within six months from issue date.

**Order from**

**Red Flower Publication Pvt. Ltd.**, 41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I, P.O. Box No. 9108, Delhi - 110 091 (India), Tel: 91-11-65270068, 48042168, Fax: 91-11-48042168. E-mail: redflowerpp1@gmail.com, redflowerpp1@vsnl.net. Website: www.rfppl.com

## Guidelines for authors

Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journal" developed by international committee of medical Journal Editors.

### Types of Manuscripts and Limits

Original articles: Up to 3000 words excluding references and abstract and up to 10 references.

Original articles: Up to 2500 words excluding references and abstract and up to 10 references.

Case reports: Up to 1000 words excluding references and abstract and up to 10 references.

### Online Submission of the Manuscripts

Articles can also be submitted online from <http://www.rfppl.com> (currently send your articles through e-mail attachments)

1) First Page File: Prepare the title page, covering letter, acknowledgement, etc. using a word processor program. All information which can reveal your identity should be here. use text/rtf/doc/PDF files. Do not zip the files.

2) Article file: The main text of the article, beginning from Abstract till References (including tables) should be in this file. Do not include any information (such as acknowledgement, your name in page headers, etc.) in this file. Use text/rtf/doc/PDF files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file.

3) Images: Submit good quality color images. Each image should be less than 100 kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 400 pixels or 3 inches). All image formats (jpeg, tiff, gif, bmp, png, eps etc.) are acceptable; jpeg is most suitable.

Legends: Legends for the figures/images should be included at the end of the article file.

If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks from submission. Hard copies of the images (3 sets), for articles submitted online, should be sent to the journal office at the time of submission of a revised manuscript. Editorial office: **Red Flower Publication Pvt. Ltd., 41/48, DSIDC, Pocket-II,**

**Mayur Vihar Phase-I, Delhi - 110 091, India,  
Phone: 91-11-22754205, Fax: 91-11-22754205, E-mail:  
[redflowerppl@gmail.com](mailto:redflowerppl@gmail.com)/[redflowerppl@vsnl.net](mailto:redflowerppl@vsnl.net).**

### Preparation of the Manuscript

The text of observational and experimental articles should be divided into sections with the headings: Introduction, Methods, Results, Discussion, References, Tables, Figures, Figure legends, and Acknowledgment. Do not make subheadings in these sections.

### Title Page

The title page should carry

1) Type of manuscript (e.g. Original article, Review article, Case Report)

2) The title of the article, which should be concise, but informative;

3) Running title or short title not more than 50 characters;

4) The name by which each contributor is known (Last name, First name and initials of middle name), with his or her highest academic degree(s) and institutional affiliation;

5) The name of the department(s) and institution(s) to which the work should be attributed;

6) The name, address, phone numbers, facsimile numbers and e-mail address of the contributor responsible for correspondence about the manuscript;

7) The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references and abstract);

8) Source(s) of support in the form of grants, equipment, drugs, or all of these;

9) Acknowledgement, if any; and

10) If the manuscript was presented as part of a meeting, the organization, place, and exact date on which it was read.

### Abstract Page

The second page should carry the full title of the manuscript and an abstract (of no more than 150 words for case reports, brief reports and 250 words for original articles). The abstract should be structured and state the Context (Background), Aims, Settings and Design, Methods and Material, Statistical analysis used, Results and Conclusions. Below the abstract should provide 3 to 10 keyword.

### Introduction

State the purpose of the article and summarize the rationale for the study or observation.

### Methods

The methods section should include only information that was available at the time the plan or protocol for the study was written; all information obtained during the conduct of the study belongs in the Results section.

Reports of randomized clinical trials should be based on the CONSORT Statement (<http://www.consort-statement.org>). When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at [http://www.wma.net/e/policy/17-c\\_e.html](http://www.wma.net/e/policy/17-c_e.html)).

### Results

Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.

### Discussion

Include Summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research). Do not repeat in detail data or other material given in the Introduction or the Results section.

### References

List references in alphabetical order. Each listed reference should be cited in text (not in alphabetic

order), and each text citation should be listed in the References section. Identify references in text, tables, and legends by Arabic numerals in square bracket (e.g. [10]). Please refer to ICMJE Guidelines ([http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)) for more examples.

#### Standard journal article

[1] Flink H, Tegelberg Å, Thörn M, Lagerlöf F. Effect of oral iron supplementation on unstimulated salivary flow rate: A randomized, double-blind, placebo-controlled trial. *J Oral Pathol Med* 2006;35:540-7.

[2] Twetman S, Axelsson S, Dahlgren H, Holm AK, Källestål C, Lagerlöf F, et al. Caries-preventive effect of fluoride toothpaste: A systematic review. *Acta Odontol Scand* 2003;61:347-55.

#### Article in supplement or special issue

[3] Fleischer W, Reimer K. Povidone iodine antiseptics. State of the art. *Dermatology* 1997;195 Suppl 2:3-9.

#### Corporate (collective) author

[4] American Academy of Periodontology. Sonic and ultrasonic scalers in periodontics. *J Periodontol* 2000;71:1792-801.

#### Unpublished article

[5] Garoushi S, Lassila LV, Tezvergil A, Vallittu PK. Static and fatigue compression test for particulate filler composite resin with fiber-reinforced composite substructure. *Dent Mater* 2006.

#### Personal author(s)

[6] Hosmer D, Lemeshow S. Applied logistic regression, 2<sup>nd</sup> edn. New York: Wiley-Interscience; 2000.

#### Chapter in book

[7] Nauntofte B, Tenovou J, Lagerlöf F. Secretion and composition of saliva. In: Fejerskov O, Kidd EAM, editors. *Dental caries: The disease and its clinical management*. Oxford: Blackwell Munksgaard; 2003. p. 7-27.

#### No author given

[8] World Health Organization. *Oral health surveys - basic methods*, 4<sup>th</sup> edn. Geneva: World Health Organization; 1997.

### Reference from electronic media

[9] National Statistics Online – Trends in suicide by method in England and Wales, 1979-2001. [www.statistics.gov.uk/downloads/theme\\_health/HSQ\\_20.pdf](http://www.statistics.gov.uk/downloads/theme_health/HSQ_20.pdf) (accessed Jan 24, 2005): 7-18. Only verified references against the original documents should be cited. Authors are responsible for the accuracy and completeness of their references and for correct text citation. The number of reference should be kept limited to 20 in case of major communications and 10 for short communications.

More information about other reference types is available at [www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html), but observes some minor deviations (no full stop after journal title, no issue or date after volume, etc).

### Tables

Tables should be self-explanatory and should not duplicate textual material.

Tables with more than 10 columns and 25 rows are not acceptable.

Number tables, in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title for each.

Explain in footnotes all non-standard abbreviations that are used in each table.

For footnotes use the following symbols, in this sequence: \*, †, ‡, §§,

### Illustrations (Figures)

Graphics files are welcome if supplied as Tiff, EPS, or PowerPoint files of minimum 1200x1600 pixel size. The minimum line weight for line art is 0.5 point for optimal printing.

When possible, please place symbol legends below the figure instead of to the side.

Original color figures can be printed in color at the editor's and publisher's discretion provided the author agrees to pay

Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations.

### Sending a revised manuscript

While submitting a revised manuscript, contributors are requested to include, along with single copy of the final revised manuscript, a photocopy of the revised manuscript with the changes underlined in red and copy of the comments with the point to point clarification to

each comment. The manuscript number should be written on each of these documents. If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks of submission. Hard copies of images should be sent to the office of the journal. There is no need to send printed manuscript for articles submitted online.

### Reprints

Journal provides no free printed reprints, however a author copy is sent to the main author and additional copies are available on payment (ask to the journal office).

### Copyrights

The whole of the literary matter in the journal is copyright and cannot be reproduced without the written permission.

### Declaration

A declaration should be submitted stating that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under the present authorship has been published or is being considered for publication elsewhere and the authorship of this article will not be contested by any one whose name (s) is/are not listed here, and that the order of authorship as placed in the manuscript is final and accepted by the co-authors. Declarations should be signed by all the authors in the order in which they are mentioned in the original manuscript. Matters appearing in the Journal are covered by copyright but no objection will be made to their reproduction provided permission is obtained from the Editor prior to publication and due acknowledgment of the source is made.

### Abbreviations

Standard abbreviations should be used and be spelt out when first used in the text. Abbreviations should not be used in the title or abstract.

### Checklist

- Manuscript Title
- Covering letter: Signed by all contributors
- Previous publication/ presentations mentioned Source of funding mentioned
- Conflicts of interest disclosed

**Authors**

- Middle name initials provided.
- Author for correspondence, with e-mail address provided.
- Number of contributors restricted as per the instructions
- Identity not revealed in paper except title page (e.g. name of the institute in Methods, citing previous study as 'our study')

**Presentation and Format**

- Double spacing
- Margins 2.5 cm from all four sides
- Title page contains all the desired information. Running title provided (not more than 50 characters)
- Abstract page contains the full title of the manuscript
- Abstract provided: Structured abstract provided for an original article.
  - Key words provided (three or more)
  - Introduction of 75-100 words
  - Headings in title case (not ALL CAPITALS). References cited in square brackets
  - References according to the journal's instructions

**Language and grammar**

- Uniformly American English
- Abbreviations spelt out in full for the first time. Numerals from 1 to 10 spelt out
- Numerals at the beginning of the sentence spelt out

**Tables and figures**

- No repetition of data in tables and graphs and in text.

- Actual numbers from which graphs drawn, provided.
- Figures necessary and of good quality (color)
- Table and figure numbers in Arabic letters (not Roman).
- Labels pasted on back of the photographs (no names written)
- Figure legends provided (not more than 40 words)
- Patients' privacy maintained, (if not permission taken)
- Credit note for borrowed figures/tables provided
- Manuscript provided on a CDROM (with double spacing)

**Submitting the Manuscript**

- Is the journal editor's contact information current?
  - Is a cover letter included with the manuscript? Does the letter
    1. Include the author's postal address, e-mail address, telephone number, and fax number for future correspondence?
    2. State that the manuscript is original, not previously published, and not under concurrent consideration elsewhere?
    3. Inform the journal editor of the existence of any similar published manuscripts written by the author?
    4. Mention any supplemental material you are submitting for the online version of your article?
- Contributors' Form (to be modified as applicable and one signed copy attached with the manuscript)

**STATEMENT ABOUT OWNERSHIP AND OTHER PARTICULARS ABOUT  
"Indian Journal of Genetics and Molecular Research" (See Rule 8)**

- |  |   |   |
|--|---|---|
| 1. Place of Publication                    | : | Delhi                                   |
| 2. Periodicity of Publication              | : | Half - Yearly                           |
| 3. Printer's Name                          | : | <b>Asharfi Lal</b>                      |
| Nationality                                | : | Indian                                  |
| Address                                    | : | 3/259, Trilok Puri, Delhi-91            |
| 4. Publisher's Name                        | : | <b>Asharfi Lal</b>                      |
| Nationality                                | : | Indian                                  |
| Address                                    | : | 3/259, Trilok Puri, Delhi-91            |
| 5. Editor's Name                           | : | <b>Asharfi Lal</b>                      |
| Nationality                                | : | Indian                                  |
| Address                                    | : | 3/259, Trilok Puri, Delhi-91            |
| 6. Name & Address of Individuals           | : | <b>Red Flower Publication Pvt. Ltd.</b> |
| who own the newspaper and particulars of   | : | <b>41/48 DSIDC, Pocket-II</b>           |
| shareholders holding more than one percent | : | <b>Mayur Vihar Phase-I</b>              |
| of the total capital                       | : | <b>Delhi - 110 091</b>                  |

I Asharfi Lal, hereby declare that the particulars given above are true to the best of my knowledge and belief.

Sd/-

**(Asharfi Lal)**

## **Indian Journal of Emergency Pediatrics**

Handsome offer for Indian Journal of Emergency Pediatrics subscribers

Subscribe **Indian Journal of Emergency Pediatrics** and get any one book or both books absolutely free worth Rs.400/-.

### **Offer and Subscription detail**

*Individual Subscriber*

One year: Rs.1000/- (select any one book to receive absolutely free)

Life membership (valid for 10 years): Rs.5000/- (get both books absolutely free)

Books free for Subscribers of **Indian Journal of Emergency Pediatrics**. Please select as per your interest. So, don't wait and order it now.

*Please note the offer is valid till stock last.*

### **CHILD INTELLIGENCE**

**By Dr. Rajesh Shukla**

ISBN: 81-901846-1-X, Pb, vi+141 Pages

Rs.150/-, US\$50/-

Published by **World Information Syndicate**

### **PEDIATRICS COMPANION**

**By Dr. Rajesh Shukla**

ISBN: 81-901846-0-1, Hb, VIII+392 Pages

Rs.250/-, US\$50

Published by **World Information Syndicate**

Order from

**Red Flower Publication Pvt. Ltd.**

41/48, DSIDC, Pocket-II, Mayur Vihar, Phase-I

P.O. Box No. 9108, Delhi - 110 091 (India)

Tel: 91-11-65270068, 22754205, Fax: 91-11-22754205

E-mail: redflowerpppl@gmail.com, redflowerpppl@vsnl.net

Website: www.rfppl.com

## Call for editorial board members & authors

### Anatomical Investigations

#### About the Journal

**The Anatomical Investigations** is a half yearly print and online journal of the **Red Flower Publication Pvt. Ltd.** publishes original and peer-reviewed articles, for the dissemination of anatomical knowledge with clinical, surgical and imaging guidance. Includes articles of history, reviews and biographies, locomotors, splachnology, neuroanatomy, imaging anatomy, anatomical variations, anatomical techniques, education and pedagogy in anatomy, Human Anatomy, Veterinary Anatomy, Embryology, Gross Anatomy (Macroscopic), Microscopic Anatomy (Histology, Cytology), Plant Anatomy (Phytotomy), Comparative Anatomy, editorials, letters to the editor, and case reports. Articles of veterinary anatomy, comparative and other morphological sciences are accepted.

#### Editor-in-Chief

Dr. Dinesh Kumar  
Associate Professor  
Dept of Anatomy  
Maualana Azad Medical College  
New Delhi - 110 002  
India  
E-mail: mamcanatomy@gmail.com

Please send your all quiries directly to the editor-in-chief or to

#### **Red Flower Publication Pvt. Ltd.**

41/48 DSIDC, Pocket-II  
Mayur Vihar Phase-I  
Delhi - 110 091, India  
Tel: 91-11-22754205, Fax: 91-11-22754205  
E-mail: redflowerppl@vsnl.net, redflowerppl@gmail.com  
Website: www.rfppl.com

## Subscription Form

I want to renew/subscribe to international class journal "**Indian Journal of Genetics and Molecular Research**" of Red Flower Publication Pvt. Ltd.

### Subscription Rates:

- India: Institutional: Rs.4000, Individual: Rs.1000, Life membership (10 years only for individuals) Rs.5000.
- All other countries: \$218

Name and complete address (in capitals):

### *Payment detail:*

Demand Draft No.

Date of DD

Amount paid Rs./USD

1. Advance payment required by Demand Draft payable to Red Flower Publication Pvt. Ltd. payable at Delhi.
2. Cancellation not allowed except for duplicate payment.
3. Agents allowed 10% discount.
4. Claim must be made within six months from issue date.

### *Mail all orders to*

#### **Red Flower Publication Pvt. Ltd.**

41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I, Delhi - 110 091 (India)

Tel: 91-11-22754205, Fax: 91-11-22754205

E-mail: redflowerppl@vsnl.net, redflowerppl@gmail.com

Website: www.rfppl.com

**Revised Rates for 2012 (Institutional)**

<b>Title</b>	<b>Frequency</b>	<b>Rate (Rs): India</b>	<b>Rate (\$):ROW</b>
Indian Journal of Anatomy	2	2500	260
Indian Journal of Ancient Medicine and Yoga	4	6000	300
Indian Journal of Dental Education	4	2500	240
Indian Journal of Emergency Pediatrics	4	5000	252
Indian Journal of Forensic Medicine & Pathology	4	10000	480
Indian Journal of Forensic Odontology	4	2500	240
Indian Journal of Genetics and Molecular Research	2	4000	218
Indian Journal of Library and Information Science	3	6000	500
Indian Journal of Pathology: Research and Practice	3	19000	795
Indian Journal of Pediatric Education	4	3000	150
Indian Journal of Surgical Nursing	3	1200	57
Journal of Psychiatric Nursing	3	1200	57
International Journal of Neurology & Neurosurgery	2	6000	230
Journal of Social Welfare and Management	4	6000	230
New Indian Journal of Surgery	4	6000	300
Physiotherapy and Occupational Therapy Journal	4	6000	300

1. Advance payment required by Demand Draft payable to Red Flower Publication Pvt. Ltd. payable at Delhi.

2. Cancellation not allowed except for duplicate payment.

3. Agents allowed 10% discount.

4. Claim must be made within six months from issue date.

**Order from**

**Red Flower Publication Pvt. Ltd.**, 41/48, DSIDC, Pocket-II, Mayur Vihar Phase-I, P.O. Box No. 9108, Delhi - 110 091 (India), Tel: 91-11-65270068, 48042168, Fax: 91-11-48042168. E-mail: redflowerpp1@gmail.com, redflowerpp1@vsnl.net. Website: www.rfpp1.com